Get the Stockscreener App
17.86
1.83%
-0.3412
Aligos Therapeutics Inc stock is traded at $17.86, with a volume of 37,546.
It is down -1.83% in the last 24 hours and up +145.09% over the past month.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$18.20
Open:
$18.17
24h Volume:
37,546
Relative Volume:
0.16
Market Cap:
$66.48M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-9.3502
EPS:
-1.91
Net Cash Flow:
$-85.33M
1W Performance:
-8.19%
1M Performance:
+145.09%
6M Performance:
+11.93%
1Y Performance:
+9.61%
1-Day Range:
$17.55
$18.25
1-Week Range:
$14.65
$24.84
52-Week Range:
$6.76
$30.00
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ALGS | 17.90 | 66.48M | 7.97M | -75.74M | -85.33M | -1.91 |
| VRTX | 448.31 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.75 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.91 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.52 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Aligos Therapeutics files $400M mixed securities shelf - MSN
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 - The Manila Times
Aligos Reports 100% HBV Suppression Success, Strong MASH Treatment Results in Clinical Trials | ALGS Stock News - StockTitan
EcoR1 Capital, LLC Increases Stake in Aligos Therapeutics Inc - GuruFocus.com
ARMISTICE CAPITAL, LLC Expands Stake in Aligos Therapeutics Inc - GuruFocus.com
Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Expands By 46.5% - MarketBeat
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Aligos Therapeutics Inc (ALGS) Quarterly 10-Q Report - Quartzy
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
U.S. Stock market top gainers: Binah Capital Group gains +107.02%, Aligos Therapeutics surges by 42.84% in mid day trading - Business Upturn
Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from HC Wainwright - Defense World
Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations - Yahoo Canada Finance
(ALGS) Technical Pivots with Risk Controls - Stock Traders Daily
Aligos Therapeutics Reports Q3 2024 Progress - TipRanks
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - The Manila Times
Aligos Reports 46% Liver Fat Reduction in MASH Trial; Q3 Loss Widens to $19.3M | ALGS Stock News - StockTitan
Aligos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aligos planning for Phase 2 trial of treatment for hepatitis B - Liver Disease News
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 - The Manila Times
(ALGS) On The My Stocks Page - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Drop in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 5.4% – Here’s What Happened - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 5.4%Here's What Happened - MarketBeat
HC Wainwright Reiterates Buy Rating for Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Aligos Therapeutics' (ALGS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 - The Manila Times
Aligos Therapeutics: ALG-055009 reduces liver fatty deposits in patients with metabolic-dysfunction associated steatohepatitis (MASH) - 2 Minute Medicine
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap UpWhat's Next? - MarketBeat
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 202 - The Manila Times
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 8.4%Should You Sell? - MarketBeat
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics (NASDAQ:ALGS) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Increase in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Trading 4.9% HigherStill a Buy? - MarketBeat
ALGS stock touches 52-week low at $7.22 amid market challenges By Investing.com - Investing.com South Africa
Aligos Therapeutics (NASDAQ:ALGS) Hits New 1-Year LowWhat's Next? - MarketBeat
ALGS stock touches 52-week low at $7.22 amid market challenges - Investing.com Australia
Adv Micro Devices (AMD-Q) QuotePress Release - The Globe and Mail
When the Price of (ALGS) Talks, People Listen - Stock Traders Daily
Aligos TherapeuticsIt's All About Chronic Hepatitis B - RTTNews
Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2% - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 6.2%Should You Sell? - MarketBeat
Aligos Therapeutics appoints new VP of Business Development By Investing.com - Investing.com Australia
Aligos Therapeutics appoints new VP of Business Development - Investing.com
Aligos Therapeutics Appoints David Perry as Vice President of Business Development - The Manila Times
Aligos Therapeutics to Present at Investor Conferences in October - The Manila Times
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):